

OMB APPROVAL
OMB Number: 3235-0416
Expires: February 28, 2006
Estimated average burden hours per response 182.00

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-QSB

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE PERIOD ENDED: September 30, 2003

COMMISSION FILE NUMBER: 333-06718

VIROPRO INC.

(Exact name of registrant as specified in its charter)

NEVADA

13-3124057

(State or other jurisdiction of
incorporation or organization)

(IRS Employer
Identification No.)

3163 Kennedy Boulevard, Jersey City, New Jersey 07306

(Address, including zip code, of principal executive offices)

(201) 217-4137

(Registrant's telephone number, including area code)

N/A

(Former name, former address & former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all documents and reports required to be filed by Sections 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filings for the past 90 days. YES (X) NO ()

APPLICABLE ONLY TO CORPORATE ISSUERS:

As of September 30, 2003, the number of the Company's shares of par value \$.001 common stock outstanding was 49,974,749.

SEC 2334 (8-03)

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

VIROPRO, INC.
FORM 10-QSB
September 30, 2003

INDEX

PART I - FINANCIAL INFORMATION

Consolidated Balance Sheet	3
Consolidated Statements of Operation	4
Consolidated Statements of Cash Flow	5
Notes to Financial Statements	6
Item 2 - Management's Discussion and Analysis of Financial Condition and Results of Operations	7
Item 3 - Controls and Procedures	8

PART II - OTHER INFORMATION

Item 1. Legal Proceedings	8
Item 2. Changes in Securities and Use of Proceeds	8
Item 3. Defaults Upon Senior Securities	8
Item 4. Submission of Matters to a Vote of Security Holders	8
Item 5. Other Information	8
Item 6. Exhibits and Reports on Form 8-K	9
SIGNATURES	9
CERTIFICATION	10

VIROPRO, INC.
FORM 10-QSB
SEPTEMBER 30, 2003

Part I - FINANCIAL INFORMATION

Item 1 - Financial Statements

VIROPRO, INC.
CONSOLIDATED BALANCE SHEET
(UNAUDITED)

Assets

September 30, 2003

Current Assets	-
Total current assets	-
Total assets	-

Liabilities and Shareholder's Equity

Current Liabilities	
Accounts payable	8,130
Total current liabilities	8,130
Shareholder's Equity	
Common Stock, \$.001 par value; authorized 50,000,000 shares; issued and outstanding 49,974,749	49,975
Paid in Capital	1,913,950
Accumulated Deficit	(1,972,055)
Total Shareholder's Equity/(Deficit)	(8,130)
Total liabilities and shareholder's equity	\$ -

Read the accompanying significant accounting notes to financial statements, which are an integral part of this financial statement.

VIROPRO, INC.
CONSOLIDATED STATEMENT OF OPERATIONS
FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2003 AND 2002

	Three months ended	
	September 30, 2003 (Unaudited)	September 30, 2002 (Unaudited)
Revenue	\$ -	\$ -
Cost of Revenue	-	-
Gross Profit	-	-
Operating expenses:		
Selling, general and administrative expenses	500	-
Total operating expenses	500	-
Income(Loss) before other income (expense)	(500)	-
Other income (expense):		
Interest expense (principally related party)	-	(14,580)
Total other income (expense)	-	(14,580)
Income (Loss) from continuing operations	(500)	(14,580)
Discontinued operations:		
Gain on assignment of subsidiary	-	-
Income (Loss) from operations of discontinued subsidiary	-	-
	-	-
Net Income (Loss)	(500)	(14,580)
Basic weighted average common shares outstanding	49,974,749	7,474,749
Basic and diluted Loss per common share	\$ (0.00)	\$ (0.00)

Read the accompanying significant accounting notes to financial statements, which are an integral part of this financial statement.

VIROPRO, INC.
STATEMENT OF CASH FLOWS
FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2003 AND 2002

	Three months ended	
	September 30, 2003	September 30, 2002
	(Unaudited)	(Unaudited)
CASH FLOWS FROM OPERATING ACTIVITIES:		
Net Income (Loss)	\$ (500)	\$ (14,580)
Changes in Operating assets and liabilities:		
Accounts Payable and Accrued Liabilities	500	14,580
Net cash provided by/(used in) operating activities	-	-
CASH FLOWS FROM INVESTING ACTIVITIES:		
Net cash provided by/(used in) investing activities	-	-
CASH FLOWS FROM FINANCING ACTIVITIES:		
Net cash provided by/(used in) financing activities	-	-
Net increase (decrease) in cash and cash equivalents	-	-
Cash and cash equivalents, beginning of period	-	-
Cash and cash equivalents, end of period	\$ -	\$ -

Supplemental information:

Pymt by shareholder of accounts payable on behalf of Company (2,500)

Read the accompanying significant accounting notes to financial statements, which are an integral part of this financial statement.

VIROPRO INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

NOTE 1 –BASIS OF PRESENTATION

The accompanying unaudited consolidated financial statements of Viropro, Inc. have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-QSB and Article 10 of Regulation S-X. The financial statements reflect all adjustments consisting of normal recurring adjustments which, in the opinion of management, are necessary for a fair presentation of the results for the periods shown. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.

These financial statements should be read in conjunction with the audited financial statements and footnotes thereto included in Viropro Inc.'s form 10-KSB as filed with the Securities and Exchange Commission.

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and that effect the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

NOTE 2 – NET EARNINGS/(LOSS) PER SHARE

Earnings (Loss) per common share are calculated under the provisions of SFAS No. 128, "Earnings per Share," which establishes standards for computing and presenting earnings per share. SFAS No. 128 requires the Company to report both basic earnings (loss) per share, which is based on the weighted-average number of common shares outstanding during the period, and diluted earnings (loss) per share, which is based on the weighted-average number of common shares outstanding plus all potential dilutive common shares outstanding. Options and warrants are not considered in calculating diluted earnings (loss) per share since considering such items would have an anti-dilutive effect.

NOTE 3 – GOING CONCERN

The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The company has reported net losses from inception totaling \$1,972,055 (unaudited). Continuation of the Company as a going concern is dependent upon obtaining sufficient working capital for its planned activity. Additional capital and/or borrowings will be necessary in order for the Company to continue in existence until attaining and sustaining profitable operations. The Company is aggressively pursuing strategic alliances which will bring a cash infusion, restructuring and a forward looking business plan.

NOTE 4 -RELATED PARTY TRANSACTIONS

In September 2003 a major shareholder controlled entity, paid \$2,500 of the Company's accounts payable on behalf of the Company. The Company and the shareholder agreed to reflect this transaction as additional paid in capital to the Company.

VIROPRO, INC.
FORM 10-QSB
September 30, 2003

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

RESULTS OF OPERATIONS THREE MONTHS ENDED SEPTEMBER 30, 2003 AND 2002.

During the three month period ending September 30, 2003, the Company's net loss was \$500 compared to a loss of \$14,580 for the same period in the prior year. The change from year to year was related to no interest accrued in the current quarter due to issuance of shares which settled a related party debt. Gross profit for the three-month periods ended March 31, 2003 and 2002 was zero dollars.

REVENUES

During the three month periods ended September 30 2003 and 2002, the Company's revenues were zero dollars. Revenues were previously derived from the sale of the insecticide products sold under the Insecta Brand name. Revenues were recognized when the product sold was shipped to the Company's customer. The absence of revenue from year to year is due to the Company ceasing its business operations due to the EPA changing the applicable regulations covering the sale and distribution of products containing the active ingredient in the Company's Insecta brand insecticide. As previously reported the Company was notified that effective December 2001 the active ingredient of its insecticide formulation could no longer be sold.

OPERATING EXPENSES

During the three months ended September 30, 2003 and 2002 the Company incurred \$500 in 2003 and zero in 2003 for operating expenses. This reflects the above-mentioned cessation of business due to changes in EPA regulations.

MATERIAL CHANGES IN FINANCIAL CONDITION, LONGEVITY AND CAPITAL RESOURCES.

At September 30, 2003, the Company had \$0 in cash and cash equivalents, the same as at the start of the fiscal year, July 01, 2003.

VIROPRO, INC.
FORM 10-QSB
September 30, 2003

Item 3. Controls and Procedures

Within the 90 days prior to the date of this report, the company carried out an evaluation, under the supervision and with the participation of the company's management, including the company's principal executive officer and principal financial officer, of the effectiveness of the design and operation of the company's disclosure controls and procedures pursuant to Exchange Act Rule 13a-14. Based upon that evaluation, the principal executive officer and principal financial officer concluded that the company's disclosure controls and procedures are effective in timely alerting them to material information relating to the company required to be included in the company's periodic SEC filings.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings.

None

Item 2. Changes in Securities.

On March 7, 2003 the Board of the Company voted to approve the issuance of 42,500,000 shares of common stock in conversion of an aggregate of \$861,366 in loans due and owing on December 31, 2002. This loan was converted at a rate per share of double the bid price for the common stock of the Company as of the date of the conversion. None of the recipients of the shares was an affiliate prior to the conversion.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Submission of Matters to a Vote of Security-Holders.

None

Item 5. Other Information.

None

Item 6. Exhibits and Reports on Form 8-K.

(a) Omitted exhibits not required.

(b) Reports on Form 8-K

The Company filed no reports on 8-K during the period covered by this report.

SIGNATURE

In accordance with the requirements of the Security Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, duly authorized.

VIROPRO, INC.

Date: November 11, 2003

By: /s/ Hugh Johnson

Hugh Johnson, President

CERTIFICATION

I, Hugh Johnson, certify that:

1. I have reviewed this quarterly report on Form 10QSB of Viropro Inc.;
2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;
3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report.
4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the small business issuer and have:
 - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the small business issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c) Evaluated the effectiveness of the small business issuer's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d) Disclosed in this report any change in the small business issuer's internal control over financial reporting that occurred during the small business issuer's most recent fiscal quarter (the small business issuer's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the small business issuer's internal control over financial reporting; and
5. I have disclosed, based on our most recent evaluation, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):
 - a) all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant's ability to record, process, summarize and report financial data and have identified for the registrant's auditors any material weaknesses in internal controls; and
 - b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls; and
6. I have indicated in this quarterly report whether or not there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

Date: November 11, 2003

By: /s/ Hugh Johnson

Hugh Johnson, President

EXHIBIT 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Viropro, Inc. (the "Company") on Form 10-QSB for the period ended September 30, 2003 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Hugh Johnson, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

- (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and,
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Date: November 11, 2003

By: /s/ Hugh Johnson

Hugh Johnson, President